secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-134767
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics Q1 net loss narrows to $8M; SNS-101 Phase 1 dose escalation complete, no DLTs
--------------------------------------------------------------------------------

- Net loss of $8.0M for Q1 2024 vs $10.2M in Q1 2023; R&D spend $4.9M, G&A $3.8M.
- Cash, cash equivalents and marketable securities $58.1M at March 31, 2024; runway into Q4 2025.
- SNS-101 Phase 1/2 dose escalation completed: 16 patients monotherapy, 18 combination; no DLTs observed.
- Topline data at ASCO 2024; dose expansion enrolling; end-of-Phase 1 FDA meeting expected by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524134767/0001193125-24-134767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524134767/d836832d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer